Jackson Creek Investment Advisors LLC Buys Shares of 65,370 Elanco Animal Health Incorporated $ELAN

Key Points

• Jackson Creek Investment Advisors initiated a new position in Elanco Animal Health, buying 65,370 shares valued at about $1.48 million in the fourth quarter.
• Insider buying was notable, with CEO Jeffrey N. Simmons and insider Rajeev A. Modi each purchasing roughly 5,000 shares in May, signaling confidence in the company.
• Elanco beat quarterly expectations, reporting EPS of $0.40 versus $0.34 expected and revenue of $1.37 billion, while analysts currently rate the stock a Moderate Buy with a consensus target price of $28.20.

Jackson Creek Investment Advisors LLC bought a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 65,370 shares of the company's stock, valued at approximately $1,479,000.

Other institutional investors have also added to or reduced their stakes in the company. Huntington National Bank boosted its stake in Elanco Animal Health by 136.7% during the 3rd quarter. Huntington National Bank now owns 1,882 shares of the company's stock valued at $38,000 after purchasing an additional 1,087 shares during the last quarter. Whittier Trust Co. of Nevada Inc. boosted its stake in Elanco Animal Health by 80.3% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company's stock valued at $42,000 after purchasing an additional 900 shares during the last quarter. Torren Management LLC purchased a new stake in Elanco Animal Health during the 4th quarter valued at $46,000. Fifth Third Bancorp boosted its stake in Elanco Animal Health by 3,018.3% during the 3rd quarter. Fifth Third Bancorp now owns 2,900 shares of the company's stock valued at $58,000 after purchasing an additional 2,807 shares during the last quarter. Finally, Farther Finance Advisors LLC boosted its stake in Elanco Animal Health by 43.6% during the 4th quarter. Farther Finance Advisors LLC now owns 3,089 shares of the company's stock valued at $70,000 after purchasing an additional 938 shares during the last quarter. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CEO Jeffrey N. Simmons bought 4,971 shares of the firm's stock in a transaction that occurred on Friday, May 15th. The shares were bought at an average cost of $20.09 per share, with a total value of $99,867.39. Following the acquisition, the chief executive officer owned 171,971 shares in the company, valued at $3,454,897.39. This trade represents a 2.98% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Rajeev A. Modi bought 4,911 shares of the firm's stock in a transaction that occurred on Friday, May 15th. The stock was bought at an average cost of $20.35 per share, for a total transaction of $99,938.85. Following the completion of the acquisition, the insider owned 160,812 shares in the company, valued at $3,272,524.20. This trade represents a 3.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 1.14% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

ELAN has been the topic of a number of research reports. Wall Street Zen downgraded Elanco Animal Health from a "strong-buy" rating to a "buy" rating in a research note on Sunday. UBS Group restated a "buy" rating on shares of Elanco Animal Health in a research note on Tuesday, March 10th. Leerink Partners raised their price target on Elanco Animal Health from $26.00 to $30.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 24th. Citigroup raised their price target on Elanco Animal Health from $30.00 to $31.00 and gave the stock a "buy" rating in a research note on Thursday, May 7th. Finally, Weiss Ratings downgraded Elanco Animal Health from a "sell (d+)" rating to a "sell (d)" rating in a research note on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $28.20.

Elanco Animal Health Stock Performance

ELAN stock opened at $23.71 on Thursday. The company has a market cap of $11.84 billion, a P/E ratio of -47.41, a price-to-earnings-growth ratio of 2.46 and a beta of 1.69. Elanco Animal Health Incorporated has a 1 year low of $12.97 and a 1 year high of $27.72. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.16 and a quick ratio of 1.12. The stock's fifty day moving average price is $23.00 and its 200-day moving average price is $23.30.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.34 by $0.06. The firm had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.28 billion. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The company's revenue for the quarter was up 14.9% on a year-over-year basis. During the same period last year, the business posted $0.37 EPS. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, equities analysts forecast that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current year.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.